WallStreetZenWallStreetZen

NASDAQ: KROS
Keros Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

KROS past revenue growth

How has KROS's revenue growth performed historically?
Company
N/A
Industry
145.73%
Market
17.2%
KROS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
KROS's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

KROS earnings and revenue history

Current Revenue
$151.0k
Current Earnings
-$153.0M
Current Profit Margin
-101,319.2%

KROS Return on Equity

Current Company
-46.7%
Current Industry
-63.5%
Current Market
188%
KROS's Return on Equity (-46.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when KROS announces earnings.

KROS Return on Assets

Current Company
-42.6%
Current Industry
2.9%
KROS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

KROS Return on Capital Employed

Current Company
-44.26%
Current Industry
19.5%
KROS's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

KROS vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
KROS$151.00k-$150.63M-$152.99M-56.77%N/A
PTCT$927.56M-$245.30M-$579.22M+28.74%N/A
GERN$237.00k-$174.78M-$184.13M-25.97%N/A
DYN$0.00-$233.48M-$235.94MN/AN/A
NTLA$36.28M-$472.22M-$481.19M+3.57%N/A
View Top Biotech Stocks

KROS earnings dates

Next earnings date
May 30, 2024

Keros Therapeutics Earnings & Revenue FAQ

What were KROS's earnings last quarter?

On Invalid Date, Keros Therapeutics (NASDAQ: KROS) reported Q4 2023 earnings per share (EPS) of -$1.34, up 21.82% year over year. Total Keros Therapeutics earnings for the quarter were -$40.24 million. In the same quarter last year, Keros Therapeutics's earnings per share (EPS) was -$1.10.

If you're new to stock investing, here's how to buy Keros Therapeutics stock.

What was KROS's earnings growth in the past year?

As of Q2 2024, Keros Therapeutics's earnings has grown year over year. Keros Therapeutics's earnings in the past year totalled -$152.99 million.

What is KROS's earnings date?

Keros Therapeutics's earnings date is Invalid Date. Add KROS to your watchlist to be reminded of KROS's next earnings announcement.

What was KROS's revenue last quarter?

On Invalid Date, Keros Therapeutics (NASDAQ: KROS) reported Q4 2023 revenue of $143.00 thousand up Infinity% year over year. In the same quarter last year, Keros Therapeutics's revenue was $0.00.

What was KROS's revenue growth in the past year?

As of Q2 2024, Keros Therapeutics's revenue has grown null year over year. Keros Therapeutics's revenue in the past year totalled $151.00 thousand.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.